SAREPTA THERAPEUTICS INC SAREPT (0L35.L) Financials
0L35.L Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 3.1 billion | 2.3 billion |
2023-06-30 | 3.1 billion | 2.4 billion |
2023-03-31 | 3.1 billion | 2.3 billion |
2022-12-31 | 3.1 billion | 2.7 billion |
0L35.L Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -155.6 million | 48.1 million |
2023-06-30 | -140.1 million | 47.4 million |
2023-03-31 | -218.9 million | 41.3 million |
2022-12-31 | -100.4 million | 50.5 million |
0L35.L Net Income
No data available :(
0L35.L Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 1.7 billion | - | - |
2023-06-30 | 1.9 billion | - | - |
2023-03-31 | 1.9 billion | - | - |
2022-12-31 | 2.0 billion | - | - |
0L35.L Shares Outstanding
0L35.L Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 40.9 million | 186.2 million | - | - |
2023-06-30 | 17.9 million | 233.8 million | - | - |
2023-03-31 | 9.5 million | 237.1 million | - | - |
2022-12-31 | 8.0 million | 205.8 million | - | - |
0L35.L Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 331.8 million | 48.0 million |
2023-06-30 | 261.2 million | 44.9 million |
2023-03-31 | 253.5 million | 46.3 million |
2022-12-31 | 258.4 million | 41.4 million |
0L35.L
Price: $129.94
52 week price:
Earnings Per Share: -4.29 USD
P/E Ratio: -29.89
Exchange: LSE
Sector: Healthcare
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Market Capitalization: 105.9 million